Last update 21 Aug 2025

GALLIUM OXODOTREOTIDE

Overview

Basic Info

Drug Type
Radiopharmaceuticals and diagnostic agent, Peptide Conjugate Radionuclide
Synonyms
gallium (68Ga) oxodotreotide
Target
SSTR2
Action
antagonists
Mechanism
SSTR2 antagonists(Somatostatin receptor 2 antagonists)
Therapeutic Areas
NeoplasmsOther Diseases
Active Indication
Neuroendocrine TumorsDiagnostic agents
Inactive Indication-
Originator Organization
Canadian Molecular Imaging Probe Consortium
Active Organization
Novartis Pharma AGCanadian Molecular Imaging Probe Consortium
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
Canada (24 Feb 2022),
Neuroendocrine Tumors
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with GALLIUM OXODOTREOTIDE
CTR20252063
/ Not yet recruitingPhase 1/2
一项在新诊断的广泛期小细胞肺癌（ES-SCLC）患者中评估 [177Lu]Lu-DOTA-TATE联合卡铂、依托泊苷和阿替利珠单抗诱导治疗及阿替利珠单抗维持治疗的安全性和疗效的Ib/II期剂量探索研究
[Translation] A phase Ib/II dose-finding study evaluating the safety and efficacy of [177Lu]Lu-DOTA-TATE combined with carboplatin, etoposide, and atezolizumab induction therapy and atezolizumab maintenance therapy in patients with newly diagnosed extensive-stage small-cell lung cancer (ES-SCLC)
100 Clinical Results associated with GALLIUM OXODOTREOTIDE
Login to view more data
100 Translational Medicine associated with GALLIUM OXODOTREOTIDE
Login to view more data
100 Patents (Medical) associated with GALLIUM OXODOTREOTIDE
Login to view more data
100 Deals associated with GALLIUM OXODOTREOTIDE
Login to view more data

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuroendocrine Tumors
Canada
Canadian Molecular Imaging Probe Consortium
24 Feb 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diagnostic agentsIND Approval
China
Novartis Pharma AG
14 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free